IVA is a high-risk, high-reward biotech stock hinging on lanifibranor’s Phase 3 NATiV3 MASH readout by Q4 2026. Click here to ...

This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent ...

Researchers have created a next-generation obesity drug that works like a “Trojan horse,” using GLP-1/GIP signals to slip a ...

Pentacyclic triterpenes are a diverse class of naturally occurring compounds characterised by five interconnected carbon rings, widely distributed in plant tissues such as bark, leaves and fruit ...

A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP ...

A new preclinical study in Nature reports a single-molecule therapy that combines GLP-1 and GIP receptor activation with triple PPAR agonism, delivering greater weight loss and metabolic benefits in ...

Cinnamon, Bitter Melon, Resveratrol, Licorice Root, Turmeric, and Coriander in the Blood Sugar Trap Liquid Tincture Formula ...

What was discovered: Researchers created a quintuple agonist that uses GLP-1 receptors to deliver a PPAR drug directly into target cells, reversing obesity and diabetes in mice. Why it matters: The ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.

Researchers at Helmholtz Munich have engineered a hybrid obesity drug that uses GLP-1 receptors to smuggle a second metabolic ...

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant ...